Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Hansa Biopharma AB

24H
Current price
2.7 EUR 0 EUR (0.00%)
Last closed 32.32 SEK
ISIN SE0002148817
Sector Healthcare
Industry Biotechnology
Exchange Stuttgart Exchange
Capitalization 2 412 363 165 SEK
Yield for 12 month +29.73 %
1Y
3Y
5Y
10Y
15Y
24H
21.11.2021 - 28.11.2021

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1 008.66 SEK

P/E ratio

Dividend Yield

Current Year

+134 417 338 SEK

Last Year

+154 897 607 SEK

Current Quarter

+48 781 340 SEK

Last Quarter

+34 416 792 SEK

Current Year

+69 433 017 SEK

Last Year

+116 327 825 SEK

Current Quarter

+37 373 904 SEK

Last Quarter

-6 208 931 SEK

Key Figures 24H

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -624 808 247 SEK
Operating Margin TTM -240.28 %
PE Ratio
Return On Assets TTM -37.08 %
PEG Ratio
Return On Equity TTM -4176.67 %
Wall Street Target Price 1 008.66 SEK
Revenue TTM 189 846 674 SEK
Book Value -4.73 SEK
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 113.1 %
Dividend Yield
Gross Profit TTM 116 327 825 SEK
Earnings per share -11.06 SEK
Diluted Eps TTM -11.06 SEK
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 24H

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 24H

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1015:964
Payout Ratio
Last Split Date 16.03.2015
Dividend Date

Stock Valuation 24H

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 14.8487
Price Sales TTM 12.7069
Enterprise Value EBITDA -3.8851
Price Book MRQ 8.0531

Financials 24H

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 24H

For 52 weeks

22.01 SEK 57.44 SEK
50 Day MA 43.21 SEK
Shares Short Prior Month
200 Day MA 38.91 SEK
Short Ratio
Shares Short
Short Percent